Physician profile
Bruce Kiessling
NPI 1386608156
$4,889.73
in general payments reported to CMS, 2019-2025
32 companies · $20.30 in 2025
The $20.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $1,185 · 2021: $1,397 · 2022: $752 · 2023: $230 · 2025: $20.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $791.16 | 2019-2023 | Breztri, Brilinta, Farxiga |
| Abbvie INC. | $612.73 | 2019-2023 | |
| Glaxosmithkline, LLC. | $461.97 | 2019-2023 | Nucala |
| Allergan, INC. | $360.17 | 2019-2020 | |
| Novo Nordisk INC | $350.17 | 2019-2022 | |
| Lilly USA, LLC | $236.75 | 2019-2023 | Mounjaro, Trulicity |
| Amarin Pharma, INC. | $218.00 | 2019-2021 | |
| Astellas Pharma US INC | $213.62 | 2020-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $180.94 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $157.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.01 | 2019-2022 | |
| Pfizer INC. | $134.46 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $129.10 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $114.75 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $81.90 | 2021-2022 | |
| Eisai INC. | $78.13 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.33 | 2019 | |
| Amgen INC. | $53.91 | 2021-2023 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $46.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.88 | 2019-2021 | |
| Alkermes, INC. | $33.20 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.98 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.79 | 2023 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $23.35 | 2021 | |
| Exact Sciences Corporation | $21.37 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.15 | 2022 | |
| Aimmune Therapeutics, INC. | $20.30 | 2025 | Zenpep |
| Abbott Laboratories | $18.75 | 2021 | |
| Medtronic, INC. | $14.05 | 2022 | |
| Vanda Pharmaceuticals INC. | $12.24 | 2021 | |
| Kaleo, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Kiessling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.